Production (Stage)
Iovance Biotherapeutics, Inc.
IOVA
$2.21
$0.167.81%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 212.68M | 164.07M | 90.86M | 32.77M | 1.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 212.68M | 164.07M | 90.86M | 32.77M | 1.90M |
| Cost of Revenue | 166.48M | 124.00M | 82.82M | 47.33M | 18.02M |
| Gross Profit | 46.20M | 40.08M | 8.04M | -14.56M | -16.11M |
| SG&A Expenses | 165.55M | 153.02M | 140.42M | 127.83M | 110.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 611.46M | 559.35M | 520.82M | 492.03M | 469.33M |
| Operating Income | -398.78M | -395.28M | -429.96M | -459.25M | -467.43M |
| Income Before Tax | -378.62M | -375.01M | -416.14M | -446.08M | -454.53M |
| Income Tax Expenses | -3.26M | -2.83M | -6.15M | -5.87M | -4.89M |
| Earnings from Continuing Operations | -375.36 | -372.18 | -410.00 | -440.22 | -449.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -375.36M | -372.18M | -410.00M | -440.22M | -449.64M |
| EBIT | -398.78M | -395.28M | -429.96M | -459.25M | -467.43M |
| EBITDA | -365.02M | -362.11M | -398.45M | -429.38M | -441.16M |
| EPS Basic | -1.23 | -1.30 | -1.50 | -1.68 | -1.82 |
| Normalized Basic EPS | -0.79 | -0.83 | -0.96 | -1.08 | -1.16 |
| EPS Diluted | -1.23 | -1.30 | -1.50 | -1.68 | -1.82 |
| Normalized Diluted EPS | -0.79 | -0.83 | -0.96 | -1.08 | -1.16 |
| Average Basic Shares Outstanding | 1.22B | 1.16B | 1.11B | 1.05B | 992.47M |
| Average Diluted Shares Outstanding | 1.22B | 1.16B | 1.11B | 1.05B | 992.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |